Lynwood Capital Management Inc. Inhibikase Therapeutics, Inc. Transaction History

Lynwood Capital Management Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$0.63 - $1.44 $75,600 - $172,800	-120,000 Closed	0 $0
Q1 2022 May 05, 2022	SELL	$1.03 - $1.77 $139,050 - $238,950	-135,000 Reduced 52.94%	120,000 $178,000
Q4 2021 Feb 11, 2022	BUY	$1.38 - $2.17 $351,900 - $553,350	255,000 New	255,000 $375,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $30.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Lynwood Capital Management Inc. with notifications on news.